Literature DB >> 25047669

Screening for late-onset Pompe disease in Finland.

Johanna Palmio1, Mari Auranen2, Sari Kiuru-Enari3, Mervi Löfberg3, Olaf Bodamer4, Bjarne Udd5.   

Abstract

Pompe disease (glycogen storage disease type II) is caused by autosomal recessive mutations in GAA gene. The estimated frequency of late-onset Pompe disease is around 1:60,000. However, only two infantile and one late-onset Pompe patients have been reported in Finland with a population of 5 million. We screened for late-onset Pompe disease in a cohort of undetermined myopathy patients with proximal muscle weakness and/or elevated serum creatine kinase values. Acid α-glucosidase (GAA) activity in dried blood spots was measured and clinical data collected in 108 patients. Four patients had low normal GAA activity; all the others had activities well within the normal range. Re-analyses of these patients did not reveal new Pompe patients. Our findings suggest that Pompe disease is extremely rare in Finland. Finland is an example of an isolated population with enrichment of certain mutations for genetic disorders and low occurrence of some autosomal recessive diseases.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glycogen storage disease type II; Late-onset; Pompe disease; Screening

Mesh:

Substances:

Year:  2014        PMID: 25047669     DOI: 10.1016/j.nmd.2014.06.438

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  5 in total

Review 1.  Molecular genetics of Pompe disease: a comprehensive overview.

Authors:  Paolo Peruzzo; Eleonora Pavan; Andrea Dardis
Journal:  Ann Transl Med       Date:  2019-07

2.  Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness.

Authors:  Zoltan Lukacs; Paulina Nieves Cobos; Stephan Wenninger; Tracey A Willis; Michela Guglieri; Marc Roberts; Rosaline Quinlivan; David Hilton-Jones; Teresinha Evangelista; Stephan Zierz; Beate Schlotter-Weigel; Maggie C Walter; Peter Reilich; Thomas Klopstock; Marcus Deschauer; Volker Straub; Wolfgang Müller-Felber; Benedikt Schoser
Journal:  Neurology       Date:  2016-05-11       Impact factor: 9.910

3.  Pompe disease in Austria: clinical, genetic and epidemiological aspects.

Authors:  W N Löscher; M Huemer; T M Stulnig; P Simschitz; S Iglseder; C Eggers; H Moser; D Möslinger; M Freilinger; F Lagler; S Grinzinger; M Reichhardt; R E Bittner; W M Schmidt; U Lex; M Brunner-Krainz; S Quasthoff; J V Wanschitz
Journal:  J Neurol       Date:  2017-11-27       Impact factor: 4.849

4.  The Latin American experience with a next generation sequencing genetic panel for recessive limb-girdle muscular weakness and Pompe disease.

Authors:  Jorge A Bevilacqua; Maria Del Rosario Guecaimburu Ehuletche; Abayuba Perna; Alberto Dubrovsky; Marcondes C Franca; Steven Vargas; Madhuri Hegde; Kristl G Claeys; Volker Straub; Nadia Daba; Roberta Faria; Magali Periquet; Susan Sparks; Nathan Thibault; Roberto Araujo
Journal:  Orphanet J Rare Dis       Date:  2020-01-13       Impact factor: 4.123

5.  Carrier frequency and predicted genetic prevalence of Pompe disease based on a general population database.

Authors:  Kyung Sun Park
Journal:  Mol Genet Metab Rep       Date:  2021-02-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.